Kinski

Piroxicam

Method of action: Analgesic, Analgetic, Anti-Inflammatory, Antiplatelet, Antipyretic, Nonsteroidal Anti-Inflammatory, Pain Reliever, Topical Products For Joint And Muscular Pain

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Pain, Osteoarthritis, Rheumatoid Arthritis, Spondylitis, Spondyloarthritis, Tendinitis, Tenosynovitis, Crush Injury

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kinski

Quick Facts

Property	Description
Active ingredient	Piroxicam
Form	Capsule, tablet, gel, injectable solution (varies)
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Symptomatic relief of pain and inflammation
Origin	Synthetic substance (oxicam derivative)

What is Kinski? Defining its Identity and Class

Kinski is the proprietary name for a medicine containing the active ingredient Piroxicam, a well-characterized synthetic substance that belongs to the oxicam class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). As an oxicam derivative, Piroxicam possesses characteristics that are clinically recognized for their relatively extended duration of action compared to many other agents in the class.

This classification confirms Kinski's fundamental function as a non-narcotic agent intended to provide relief by modulating the body's inflammatory and pain responses. The drug's characteristics are standardized through established pharmaceutical synthesis, positioning it as a researched compound for pain and inflammation management in patients requiring this specific profile.

Composition and Available Pharmaceutical Forms

The core of Kinski's composition is Piroxicam, which is blended with necessary pharmaceutical excipients to create stable preparations. Kinski is available in various dosage form(s) to accommodate both systemic administration and localized treatment, reflecting its versatility in application.

Forms for systemic administration typically include the oral capsule, tablet, and injectable solution, intended for a widespread effect. However, a differentiating factor is its availability as localized treatment forms, such as the gel, topical preparation, and cutaneous foam. The inclusion of Piroxicam in topical preparations allows for targeting symptoms at a specific external site while limiting internal exposure. The use of Piroxicam beta-cyclodextrin in some formulations is an additional distinguishing feature, potentially designed to improve the compound's absorption rate.

General Purpose and Therapeutic Action

The general purpose of Kinski is to provide effective symptomatic relief for inflammation and pain. It achieves this by leveraging its strong anti-inflammatory effect and complementary analgesic effect.

This action is focused on interfering with the signals that cause pain and swelling. The drug's dual capability allows it to manage discomfort and reduce swelling associated with inflammatory conditions, making it useful in typical scenarios such as managing pain during the recovery phase from an orthopedic injury or a flare-up of a rheumatic condition.

What side effects are possible with Kinski?

Kinski: Possible Side Effects and Safety Information

This section details the adverse reactions and safety constraints for Kinski as formally documented in government regulatory sources (e.g., FDA, EMA). All information is non-advisory and reflective of the official safety profile.

Adverse Reaction Scope

Side effects are categorized by frequency and System-Organ-Class (SOC), providing a structured view of the risk profile. Regulatory documents use standardized frequency bands:

Frequency Classification	Definition
Very Common	Occurs in ge 1 in 10 patients
Common	Occurs in ge 1 in 100 to < 1 in 10 patients
Uncommon	Occurs in ge 1 in 1,000 to < 1 in 100 patients

Major System-Organ Classes typically involved include Gastrointestinal disorders, Nervous system disorders, and Blood and lymphatic system disorders, among others.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights Serious Adverse Reactions (SARs), which are rare but clinically significant. These may include life-threatening events such as severe hypersensitivity reactions (e.g., anaphylaxis) or organ-specific toxicities like Hepatic Failure or severe Neutropenia.

Population-Specific Safety: Explicit statements may restrict use or require dose adjustments in patients with severe renal or hepatic impairment. Separate safety considerations are documented for use during pregnancy and lactation.

Safety Restrictions: The label lists Contraindications (absolute prohibitions on use) and specifies high-level Safety Warnings (e.g., risk of QT interval prolongation, need for specific pre-treatment screening). Patients must also adhere to monitoring requirements, such as scheduled laboratory tests (e.g., LFTs, CBCs), as defined in the official documentation.

The overall safety profile is structured to clearly define the known and potential risks, distinguishing common, expected reactions from rare, serious adverse events under defined conditions of use.

Overdose and Emergency Response

Kinski Overdose and When to Seek Help

An overdose occurs when a toxic amount of a substance is consumed, overwhelming the body's systems and potentially leading to life-threatening complications. In any situation where a significant excess of Kinski is suspected, immediate medical attention is a critical requirement.

Documented Overdose Signs

Overdose presentations can vary widely depending on the substance’s class, but authoritative health sources define severe overdose by a progression of central nervous system and cardiorespiratory symptoms. Clinical manifestations of a severe drug overdose often include:

Breathing Difficulties: Slowed, shallow, or stopped breathing is a primary concern in many types of overdose.
Altered Consciousness: Marked mental confusion, profound stupor, or complete unresponsiveness to stimulation.
Cardiovascular Changes: Dangerously high or low blood pressure, or a heart rate that slows, becomes irregular, or stops.

Emergency Response and Urgent Care

If any of the above serious signs are present, or if an overdose is merely suspected, call emergency services immediately and remain with the individual until help arrives. This urgent step is necessary to secure the person's airway and circulation, which is the cornerstone of emergency overdose management.

Specific management by medical professionals may involve supportive care, such as assistance with breathing, and the administration of an antidote if one is available and applicable to the substance involved. Never attempt to treat an overdose without qualified medical assistance.

Therapeutic Uses of Kinski

Kinski is relevant in clinical settings where supportive symptom management is appropriate, applied across domains involving inflammatory or irritative states. The primary therapeutic benefit of this medication is providing supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load during periods of heightened discomfort.

Kinski is commonly used for managing symptomatic manifestations in chronic conditions like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis, as well as during episodes of acute gout. It helps address symptom clusters that may create noticeable physiological strain, such as persistent joint swelling, tenderness, and debilitating daily stiffness.

It is applied in scenarios where additional management of discomfort is required, offering symptomatic relief that may help patients cope more steadily with difficult episodes. This medication is commonly used to help patients manage the fluctuating symptoms of long-term joint conditions.

Quick Fact: Relief for Joint Inflammation
Kinski is used for managing conditions characterized by periods of heightened symptoms, often targeting the pain and physical discomfort associated with active inflammatory processes in the joints.

Regulatory References

NIH DailyMed overview of Piroxicam uses

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Kinski (Piroxicam) — Official Regulatory Information

Kinski (Piroxicam) is generally approved for use in the adult population for its indicated symptomatic relief. However, regulatory documents define several absolute prohibitions and restrictions based on patient population and medical history.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (typically 18 years and older) for officially documented symptomatic treatment of conditions like Osteoarthritis and Rheumatoid Arthritis.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Piroxicam, Aspirin, or other NSAIDs; history of active gastrointestinal ulceration or bleeding; and for treating pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Age-related eligibility rules	Use is not established in the pediatric population. Older adults require caution due to increased risks, and use may be avoided in those over 80 years old.
Condition-specific eligibility rules	Avoid use in patients with advanced renal disease or severe heart failure. Dehydration or hypovolemia must be corrected prior to administration.
Pregnancy and lactation eligibility status	Contraindicated in the third trimester (starting at 30 weeks gestation). Use is restricted between 20 and 30 weeks gestation. Use during lactation requires caution and a risk-benefit assessment, as Piroxicam is excreted in human milk.

Official eligibility statements:

Kinski is contraindicated in patients with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.
The medicine must not be used in women starting at 30 weeks gestation.
Use is avoided in patients with severe, uncompensated heart failure or advanced renal disease.

These rules establish absolute contraindications based on hypersensitivity, specific cardiovascular risks, and pre-existing severe comorbidities, defining who is formally prohibited from using the medicine according to regulatory standards.

What should I know about interactions with other medicines?

Kinski's (Piroxicam) interaction profile is defined by formal contraindications and documented effects on drug metabolism and efficacy.

Contraindicated Combinations

Co-administration with the following is formally contraindicated by regulatory authorities: other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, and Acetylsalicylic acid (Aspirin) when used at analgesic doses. This prohibition is due to an elevated, additive risk of serious gastrointestinal complications, such as ulceration and bleeding. Concomitant use with oral Anticoagulants is also contraindicated, as it creates a synergistic effect that significantly increases the risk of serious bleeding.

Pharmacodynamic and Metabolic Interactions

Kinski may diminish the antihypertensive or natriuretic effect of agents like Diuretics, ACE Inhibitors, and ARBs. This combination carries a specific caution regarding the potential for deterioration of renal function in high-risk populations, including the elderly. The medicine can also increase the plasma concentration and prolong the half-life of Lithium and Digoxin by inhibiting their clearance.

Kinski is primarily metabolized by the CYP2C9 enzyme. Regulatory documents specify that individuals identified as CYP2C9 poor metabolizers may experience abnormally high systemic exposure to the medicine due to reduced metabolic clearance. While administration with food only causes a slight delay in the rate of absorption, consumption of alcohol is cited as an official risk factor that increases the overall risk of serious gastrointestinal complications.

Mechanism of Action

Non-Selective Inhibition of Prostaglandin Synthesis

Kinski primarily works by non-selectively inhibiting the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2), which are responsible for the biosynthesis of prostaglandins ( PGs). This mechanism suppresses the production of these key chemical mediators, leading to a cascade that modulates multiple physiological responses.

Modulation of Nociceptive and Vascular Signals

The resulting reduction in PGs limits their ability to sensitize peripheral pain nerve endings (nociceptors), thereby increasing the stimulus intensity required to activate peripheral pain nerves. Concurrently, limiting PGs also restricts the localized vasodilation and increased microvascular permeability, which helps to modulate microvascular tone and limit the rate of fluid extravasation.

Contextual Constraints on Homeostatic Pathways

The non-selective nature of the mechanism means it affects both inducible COX-2 and constitutive COX-1 isoforms. This inherent mechanistic boundary involves the COX-1-mediated synthesis of prostaglandins in the gastric mucosa and the PG-mediated regulation of renal blood flow under conditions of physiological stress.

Dosage and Administration Information

How to Use Kinski (Piroxicam): Official Administration Guidelines

Kinski, which contains the active ingredient Piroxicam, is administered according to strict official protocols that define the route, frequency, and maximum permitted dosage. The medicine is primarily used via the Oral route (capsule or tablet), but is also approved for Intramuscular (IM) Injection and Rectal administration.

Official Dosing and Frequency

The standard maintenance regimen for chronic conditions like Osteoarthritis and Rheumatoid Arthritis is typically 20 mg taken once daily. Alternatively, the dose may be divided into 10 mg taken twice daily. For acute episodes, such as gout, the official dosage involves a short course starting with 40 mg daily, which may be given in a single or divided dose, before stepping down to a lower amount.

Since Piroxicam has a prolonged presence in the body, the full therapeutic effect is not officially assessed until 7 to 12 days after treatment initiation.

Administration Conditions and Adjustments

Oral forms must be taken with food, milk, or a full glass of water (8 to 12 oz) to ensure proper intake. Capsules and tablets should be swallowed whole.

Special Use Restrictions:

IM Injection is restricted to a maximum of 2 to 3 days of therapy.
Older adults and patients with specific metabolic profiles should consider initiating therapy at the low end of the dosing range (e.g., 10 mg daily).
If a dose is missed, it should be taken as soon as remembered, but never double the dose to make up for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kinski (Piroxicam)

This overview summarizes the types of scientific studies that have been conducted for Kinski (Piroxicam) as reported by regulatory and scientific sources. The focus is strictly on the structure of the evidence and what researchers observed, without offering clinical recommendations or individual advice.

Research Evidence for Kinski in Osteoarthritis

The research base for Kinski in this setting primarily involves Randomized Controlled Trials (RCTs) and meta-analyses. These studies were used in research exploring how symptoms change over time in adult patients with radiographically confirmed osteoarthritis (a condition characterized by functional limitations).

Researchers examined outcomes related to physical discomfort, as well as outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies related to short-term symptom changes. What remains uncertain is the long-term characterization of the effects; many trials had short-term follow-up durations.

Research Evidence for Kinski in Rheumatoid Arthritis

Kinski was also studied in Randomized Controlled Trials for Rheumatoid Arthritis, a condition characterized by fluctuating or episodic manifestations. Research examined multiple outcomes linked to inflammatory or irritative states such as objective measurements of joint tenderness and swelling, and subjective reports like the duration of morning stiffness. A key limitation is that the research focusing on episodes where symptoms become more noticeable is mainly observational of short-term symptom patterns.

Duration of Studies and Long-Term Follow-Up

Research exploring short-term symptom changes is well-documented, but the available scientific literature suggests that long-term effects are not fully established based on a comprehensive set of current large-scale RCTs. Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain—about the durability of the observed responses.

Evidence in Specific Patient Groups

Kinski was studied in specific populations, with evidence describing the observed patterns in older adults. Regulatory reviews suggest that older adults was associated with greater sensitivity in regulatory reports. For the pediatric population, research exploring outcomes related to physical discomfort has not been characterized, and data for children remain insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Kinski (FAQ)

Q: What is Kinski used for?

Kinski is a prescription medication indicated for the management of symptoms associated with Condition X, as defined in the official prescribing information.

Q: How should I take Kinski?

The administration of Kinski should strictly follow the instructions provided by your healthcare provider. Do not adjust your regimen without professional medical guidance. The official product labeling provides specific directions for proper use.

Q: Is Kinski safe for long-term use?

Safety for long-term use is typically addressed through ongoing consultation with a healthcare professional. While some patients may use Kinski for extended periods, the continued need for the medication should be regularly evaluated by your doctor.

Q: What should I do if I miss a dose?

If a dose is missed, patients should refer to the specific guidance in the product labeling or contact their doctor or pharmacist for advice. Do not take two doses at once to make up for a missed dose unless specifically directed by a medical professional.

How should Kinski be stored and disposed of?

How to Store and Dispose of Kinski (Piroxicam)

The medicine Kinski must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Requirements

Kinski must be stored at Controlled Room Temperature, typically 15 C to 30 C. Storage above this range is prohibited. The container must be kept tightly closed and in the packaging it came in to protect from light and moisture. To prevent accidental ingestion, the medication must be kept out of reach of children and stored locked up.

Disposal Instructions

Unused or expired Kinski must be disposed of in accordance with local and national regulations for pharmaceutical waste. Patients should consult a healthcare professional or local waste management authority for specific instructions on discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Italy

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z